FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/07/091569 [Registered on: 24/07/2025] Trial Registered Prospectively
Last Modified On: 23/07/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Biological 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Treatment of gum recession using growth factor therapy  
Scientific Title of Study   Efficacy of recombinant human fibroblast growth factor impregnated scaffold in the management of isolated maxillary gingival recession - A randomised controlled clinical trial 
Trial Acronym  Nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DrSaravanan SP 
Designation  Assistant Professor 
Affiliation  Army Dental Centre Research Referral Delhi 
Address  Room No 205 First Floor Dept of Periodontology Army Dental Centre Research and Referral Delhi India
Army Dental Centre Research and Referral Delhi India
South
DELHI
110010
India 
Phone  9637110906  
Fax    
Email  saravananacademics@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DrSaravanan SP 
Designation  Assistant Professor 
Affiliation  Army Dental Centre Research Referral Delhi 
Address  Room No 205 First Floor Dept of Periodontology Army Dental Centre Research and Referral Delhi India
Army Dental Centre Research and Referral Delhi India

DELHI
110010
India 
Phone  9637110906  
Fax    
Email  saravananacademics@gmail.com  
 
Details of Contact Person
Public Query
 
Name  DrSaravanan SP 
Designation  Assistant Professor 
Affiliation  Army Dental Centre Research Referral Delhi 
Address  Room No 205 First Floor Dept of Periodontology Army Dental Centre Research and Referral Delhi India
Army Dental Centre Research and Referral Delhi India

DELHI
110010
India 
Phone  9637110906  
Fax    
Email  saravananacademics@gmail.com  
 
Source of Monetary or Material Support  
Army Dental Centre Research and Referral Dhaula Kuan Delhi Cantonment Delhi 110010 
 
Primary Sponsor  
Name  Indian Army 
Address  Director General Armed Forces Medical Services Room A402 Block A 4th Floor Africa Avenue New Delhi 110023 
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Saravanan SP  Army Dental Centre Research and Referral   Room No 205 First Floor Dept of Periodontology Delhi Cantonment 110010
South
DELHI 
9637110906

saravananacademics@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Army Dental centre  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K055||Other periodontal diseases,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Control   Collagen scaffold with placebo impregnation will be used for management of isolated maxillary gingival recession in combination with coronally advanced flap will be performed and the patient will be followed up to 12 months 
Intervention  FGF group   Recombinant human fibroblast growth factor impregnated collagen scaffold will be used as soft tissue substitute for treatment of isolated gingival recession in maxilla in combination with coronally advanced flap will be performed and the patient will be followed up to 12 months 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  45.00 Year(s)
Gender  Both 
Details  RT1 type recession
Maxillary gingival recession
Isolated gingival recession
Thin soft tissue phenotype
FMBS less than 20
FMPS less than 20 
 
ExclusionCriteria 
Details  mokers
Tobacco users
Pregnancy
Lactating mothers
Not available for 24 months follow up
Unwilling for periodic recall every 3 months 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant, Investigator and Outcome Assessor Blinded 
Primary Outcome  
Outcome  TimePoints 
Changes in recession height
Changes in recession width
Mean root coverage
Complete root coverage
Visual analog scale
Patient reported outcome measures  
Baseline, 3 Months, 6 Months, 9 Months, 12 Months 
 
Secondary Outcome  
Outcome  TimePoints 
Patient satisfaction
Incidence of complications  
0,3,6,9,12 months 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   20/08/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Recombinant human fibroblast growth factor (rhFGF) has shown promising results in the treatment of isolated maxillary gingival recession defects. When used in conjunction with a coronally advanced flap or biomaterials like collagen membranes, rhFGF enhances angiogenesis, promotes fibroblast proliferation, and accelerates periodontal tissue regeneration. Clinical outcomes demonstrate improved root coverage, increased keratinized tissue width, and superior soft tissue aesthetics, making rhFGF a valuable adjunct in regenerative periodontal therapy for localized recession. However there is no single study available on this in India. Hence this clinical trial.  
Close